Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.830EUR
−66.70 MEUR
7.57 MEUR
29.17 M
About MOLECULAR PARTNERS N
Sector
Industry
CEO
Patrick Amstutz
Website
Headquarters
Schlieren
Employees (FY)
182
Founded
2004
ISIN
CH0256379097
FIGI
BBG0079TC1D1
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on BER exchange MOLECULAR PARTNERS SF 1 stocks are traded under the ticker 6ML.
We've gathered analysts' opinions on MOLECULAR PARTNERS SF 1 future price: according to them, 6ML price has a max estimate of 17.37 EUR and a min estimate of 3.06 EUR. Watch 6ML chart and read a more detailed MOLECULAR PARTNERS SF 1 stock forecast: see what analysts think of MOLECULAR PARTNERS SF 1 and suggest that you do with its stocks.
Yes, you can track MOLECULAR PARTNERS SF 1 financials in yearly and quarterly reports right on TradingView.
MOLECULAR PARTNERS SF 1 is going to release the next earnings report on Aug 26, 2024. Keep track of upcoming events with our Earnings Calendar.
MOLECULAR PARTNERS SF 1 revenue for the last quarter amounts to 2.78 M EUR, despite the estimated figure of 2.77 M EUR. In the next quarter, revenue is expected to reach 827.13 K EUR.
6ML net income for the last quarter is −11.63 M EUR, while the quarter before that showed −21.29 M EUR of net income which accounts for 45.34% change. Track more MOLECULAR PARTNERS SF 1 financial stats to get the full picture.
No, 6ML doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 13, 2024, the company has 182.00 employees. See our rating of the largest employees — is MOLECULAR PARTNERS SF 1 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MOLECULAR PARTNERS SF 1 EBITDA is −61.09 M EUR, and current EBITDA margin is −833.87%. See more stats in MOLECULAR PARTNERS SF 1 financial statements.
Like other stocks, 6ML shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MOLECULAR PARTNERS SF 1 stock right from TradingView charts — choose your broker and connect to your account.